Maternal and perinatal outcomes of pre-referral magnesium sulfate treatment in severe preeclampsia patients
HIGHLIGHTS 1. Consumption of magnesium sulfate is recommended for prevention against eclampsia. 2. Magnesium sulfate administration to preeclamptic mothers is effective in reducing the risk of eclampsia. 3. Pre-referral magnesium sulfate administration and maternal and perinatal outcomes in sever...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Airlangga
2022-04-01
|
| Series: | Majalah Obstetri dan Ginekologi |
| Subjects: | |
| Online Access: | https://e-journal.unair.ac.id/MOG/article/view/25452 |
| _version_ | 1811267065084903424 |
|---|---|
| author | Rizki Amalia Sari Sulistiawati Sulistiawati Ernawati Ernawati |
| author_facet | Rizki Amalia Sari Sulistiawati Sulistiawati Ernawati Ernawati |
| author_sort | Rizki Amalia Sari |
| collection | DOAJ |
| description | HIGHLIGHTS
1. Consumption of magnesium sulfate is recommended for prevention against eclampsia.
2. Magnesium sulfate administration to preeclamptic mothers is effective in reducing the risk of eclampsia.
3. Pre-referral magnesium sulfate administration and maternal and perinatal outcomes in severe preeclampsia patients was analyzed.
4. Magnesium sulfate did reduce eclampsia risk, but not ICU and NICU care rates, maternal mortality, perinatal asphyxia, and perinatal mortality.
ABSTRACT
Objectives: This study analyzed the association between pre- referral magnesium sulfate administration and maternal and perinatal outcomes in severe preeclampsia patients.
Materials and Methods: This was a retrospective observational analytic study using cross-sectional design. Samples were 132 pregnant women with preeclampsia referred to dr. Saiful Anwar, Hospital Malang, Indonesia in 2019. Data were taken from the patients’ medical records. Maternal outcomes measured in this study were the incidence of eclampsia, ICU care, and maternal mortality, while the perinatal outcomes included the incidence of asphyxia, NICU care, and perinatal mortality.
Results: Patients’ history of magnesium sulphate administration significantly associated with the incidence of eclampsia with p-value 0.035 and odds ratio (OR) 2.413, thus consumption of magnesium sulphate could reduce the risk of seizures. However, it did not associate with either maternal ICU care outcomes (p-value 0.087, OR 2.028), or maternal mortality (p-value 0.573). No relationship was found neither between history of magnesium sulphate administration in pregnant women with severe preeclampsia and perinatal outcomes nor with the incidence of asphyxia (p-value 0. 577, OR 0.795), with NICU treatment (p-value 0.205, OR 0.579), and with perinatal mortality (p-value 0.153, OR 3.259).
Conclusion: Magnesium sulfate reduced the risk of eclampsia, yet it did not affect either the rate of ICU care, maternal mortality, incidence rate of perinatal asphyxia, the rate of NICU care, or perinatal mortality. |
| first_indexed | 2024-04-12T20:54:37Z |
| format | Article |
| id | doaj.art-51110f4c4e644627bc2a7b49c59364e8 |
| institution | Directory Open Access Journal |
| issn | 0854-0381 2598-1013 |
| language | English |
| last_indexed | 2024-04-12T20:54:37Z |
| publishDate | 2022-04-01 |
| publisher | Universitas Airlangga |
| record_format | Article |
| series | Majalah Obstetri dan Ginekologi |
| spelling | doaj.art-51110f4c4e644627bc2a7b49c59364e82022-12-22T03:17:01ZengUniversitas AirlanggaMajalah Obstetri dan Ginekologi0854-03812598-10132022-04-01301172310.20473/mog.V30I12022.17-2320854Maternal and perinatal outcomes of pre-referral magnesium sulfate treatment in severe preeclampsia patientsRizki Amalia Sari0https://orcid.org/0000-0002-8999-9804Sulistiawati Sulistiawati1https://orcid.org/0000-0003-2193-6679Ernawati Ernawati2https://orcid.org/0000-0002-9344-3606Midwifery Study Program, Faculty of Medicine, Universitas Airlangga, SurabayaDepartment of Public Health and Preventive Medicine, Faculty of Medicine, Universitas Airlangga, SurabayaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, SurabayaHIGHLIGHTS 1. Consumption of magnesium sulfate is recommended for prevention against eclampsia. 2. Magnesium sulfate administration to preeclamptic mothers is effective in reducing the risk of eclampsia. 3. Pre-referral magnesium sulfate administration and maternal and perinatal outcomes in severe preeclampsia patients was analyzed. 4. Magnesium sulfate did reduce eclampsia risk, but not ICU and NICU care rates, maternal mortality, perinatal asphyxia, and perinatal mortality. ABSTRACT Objectives: This study analyzed the association between pre- referral magnesium sulfate administration and maternal and perinatal outcomes in severe preeclampsia patients. Materials and Methods: This was a retrospective observational analytic study using cross-sectional design. Samples were 132 pregnant women with preeclampsia referred to dr. Saiful Anwar, Hospital Malang, Indonesia in 2019. Data were taken from the patients’ medical records. Maternal outcomes measured in this study were the incidence of eclampsia, ICU care, and maternal mortality, while the perinatal outcomes included the incidence of asphyxia, NICU care, and perinatal mortality. Results: Patients’ history of magnesium sulphate administration significantly associated with the incidence of eclampsia with p-value 0.035 and odds ratio (OR) 2.413, thus consumption of magnesium sulphate could reduce the risk of seizures. However, it did not associate with either maternal ICU care outcomes (p-value 0.087, OR 2.028), or maternal mortality (p-value 0.573). No relationship was found neither between history of magnesium sulphate administration in pregnant women with severe preeclampsia and perinatal outcomes nor with the incidence of asphyxia (p-value 0. 577, OR 0.795), with NICU treatment (p-value 0.205, OR 0.579), and with perinatal mortality (p-value 0.153, OR 3.259). Conclusion: Magnesium sulfate reduced the risk of eclampsia, yet it did not affect either the rate of ICU care, maternal mortality, incidence rate of perinatal asphyxia, the rate of NICU care, or perinatal mortality.https://e-journal.unair.ac.id/MOG/article/view/25452pre-referralmagnesium sulfatesevere preeclampsiamaternal outcomesperinatal outcomesmaternal health |
| spellingShingle | Rizki Amalia Sari Sulistiawati Sulistiawati Ernawati Ernawati Maternal and perinatal outcomes of pre-referral magnesium sulfate treatment in severe preeclampsia patients Majalah Obstetri dan Ginekologi pre-referral magnesium sulfate severe preeclampsia maternal outcomes perinatal outcomes maternal health |
| title | Maternal and perinatal outcomes of pre-referral magnesium sulfate treatment in severe preeclampsia patients |
| title_full | Maternal and perinatal outcomes of pre-referral magnesium sulfate treatment in severe preeclampsia patients |
| title_fullStr | Maternal and perinatal outcomes of pre-referral magnesium sulfate treatment in severe preeclampsia patients |
| title_full_unstemmed | Maternal and perinatal outcomes of pre-referral magnesium sulfate treatment in severe preeclampsia patients |
| title_short | Maternal and perinatal outcomes of pre-referral magnesium sulfate treatment in severe preeclampsia patients |
| title_sort | maternal and perinatal outcomes of pre referral magnesium sulfate treatment in severe preeclampsia patients |
| topic | pre-referral magnesium sulfate severe preeclampsia maternal outcomes perinatal outcomes maternal health |
| url | https://e-journal.unair.ac.id/MOG/article/view/25452 |
| work_keys_str_mv | AT rizkiamaliasari maternalandperinataloutcomesofprereferralmagnesiumsulfatetreatmentinseverepreeclampsiapatients AT sulistiawatisulistiawati maternalandperinataloutcomesofprereferralmagnesiumsulfatetreatmentinseverepreeclampsiapatients AT ernawatiernawati maternalandperinataloutcomesofprereferralmagnesiumsulfatetreatmentinseverepreeclampsiapatients |